Currently Viewing:
Community Oncology Alliance
Rose Gerber's Outlook on the Evolution and Goals of COA'S CPAN
July 13, 2017
Dr Barbara McAneny Discusses the Continuing Evolution of the COME HOME Model
July 07, 2017
Dr Basit Chaudhry on the Impact of the Oncology Care Model
July 05, 2017
Rose Gerber Discusses Cancer Survivorship's Lifelong Side Effects
June 30, 2017
Dr Bobby Green Explains How Changing Oncology Landscape Drives Big Data Initiatives
June 23, 2017
Leah Ralph on the Political and Legal Obstacles to 340B Reform
June 20, 2017
Leah Ralph: ACCC Concerned About Potential Impact of MedPAC Proposals
May 28, 2017
Dr Daniel George on the Challenge of Cancer Vaccines
May 04, 2017
Big Data Is Advancing Cancer Care, but Interoperability Remains a Challenge
May 03, 2017
Leah Ralph on ACCC's Concerns With GOP Healthcare Reform Proposals
April 30, 2017
Linking Claims, Clinical Data Is Essential for a Learning Health System
April 28, 2017
Dr Basit Chaudhry: Feedback Provides Potential Changes for the OCM
April 28, 2017
Christian Downs on the Importance of Developing the Oncology Workforce
April 28, 2017
Oncologists Believe Achieving Cancer Moonshot Goals Should Start in the Community
April 28, 2017
Oncology Practice Administrators Discuss Early Findings From the OCM
April 27, 2017
Rose Gerber: Cancer Patients Made Their Voices Heard on Capitol Hill
April 27, 2017
Congressman, Pharmacist, and Lawyer Debate PBMs, Drug Prices at Annual COA Meeting
April 27, 2017
Currently Reading
Dr Barbara McAneny on Leveling the Playing Field for Community Oncology
April 27, 2017

Dr Barbara McAneny on Leveling the Playing Field for Community Oncology

The playing field regarding Medicare reimbursement and drug pricing has to be leveled between hospitals and community oncologists in order for physicians to compete for patients on the basis of the quality of care they provide,


The playing field regarding Medicare reimbursement and drug pricing has to be leveled between hospitals and community oncologists in order for physicians to compete for patients on the basis of the quality of care they provide, said Barbara McAneny, MD, chief medical officer of New Mexico Oncology Hematology Consultants.

Transcript

What are the most significant struggles facing stand-alone oncology clinics in the community?

Stand-alone clinics for cancer have increasing drug costs and decreasing reimbursement. We have to have a significant infrastructure to be able to safely get the chemotherapy out of the little bottles and put it safely into a patient. We did an experiment in our office: we looked at how much does it cost me in terms of pharmacy infrastructure, having the right refrigerators, having all the right regulatory concerns met, having the appropriate personnel—pharmacists, oncology nurses—and how much does it cost to get the drugs out of the little bottles and into the patient safely, and Medicare pays about 40% of that cost.

So the main threat to community oncologists is that we have to safely deliver expensive chemotherapy drugs and we are not paid sufficiently to actually administer those drugs. Medicare assumes that the drug quote margin, the ASP [Average Sales Price] plus 4.3%, is actually profit. It is not. It does not even make up the shortfall in what Medicare pays us to deliver those drugs in a safe environment to our patients. We need to have realistic pricing, if community oncology is going to continue to do well.

There's also no reason why hospitals can get 340B pricing so they can buy our most expensive supply at about 72% to 75% of what we buy it for and be paid more and be tax exempt in many instances. That's a difficult competition. We need to level that playing field. We need to allow physicians to be able to compete for patients on the basis of quality of care they give, the personal care we give in terms of sort of customer service, and be able to compete not based on who signs your paycheck on the front. We really need to level that playing field and let community oncology compete in a fair field.

If we do that, then I think patients will recognize that the value that they get from an independent practice is so much greater than the value that they get from a large, vertically integrated institution. Then community oncology will do well.

 
Copyright AJMC 2006-2017 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!